Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria

Allergy and Asthma Proceedings

Volumn 32, Issue 6, 2011, Pages 460-466

  Magen, Eli ^a,b   Mishal, Joseph ^b   Zeldin, Yuri ^b   Schlesinger, Menachem ^b  

^a Leumit Health Care System   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4;

ANGIONEUROTIC EDEMA; ARTICLE; BLOOD CELL COUNT; CHRONIC IDIOPATHIC URTICARIA; CONTROLLED STUDY; DERMOGRAPHISM; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRICK TEST; SCORING SYSTEM; THROMBOCYTE VOLUME; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA; URTICARIA ACTIVITY SCORE;

ADULT; CHRONIC DISEASE; DRUG RESISTANCE; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URTICARIA;

EID: 84455188399     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2011.32.3483     Document Type: Article

References (46)

1. 2LEN/EDF/WAO guideline: Definition, classification and diagnosis of urticaria. Allergy 64:1417-1426, 2009.
2. Najib U, and Sheikh J. The spectrum of chronic urticaria. Allergy Asthma Proc 30:1-10, 2009.
3. Staubach P, Eckhardt-Henn A, Dechene M, et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 154:294-298, 2006. (Pubitemid 43382700)
4. 2LEN/EDF/WAO guideline: Management of urticaria. Allergy 64:1427-1443, 2009.
5. Staevska M, Popov T, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 125:676-682, 2010.
6. Siebenhaar F, Degener F, Zuberbier T, et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebocontrolled, crossover study. J Allergy Clin Immunol 123:672-679, 2009.
7. Kameyoshi Y, Tanaka T, Mihara S, et al. Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: An open study of 21 patients. Br J Dermatol 157:803-804, 2007.
8. Hampel F, Ratner P, and Haeusler JM. Safety and tolerability of levocetirizine dihydrochloride in infants and children with allergic rhinitis or chronic urticaria. Allergy Asthma Proc 31:290-295, 2010.
9. Goetz DW. Vitamin D treatment of idiopathic itch, rash, and urticaria/angioedema. Allergy Asthma Proc 31:158-160, 2010.
10. 2LEN task force report. Allergy 66:317-330, 2011.
11. Altrich ML, Halsey JF, and Altman LC. Comparison of the in vivo autologous skin test with in vitro diagnostic tests for diagnosis of chronic autoimmune urticaria. Allergy Asthma Proc 30:28-34, 2009.
12. Asero R, Tedeschi A, Coppola R, et al. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol 119:705-710, 2007. (Pubitemid 46335814)
13. Asero R, Tedeschi A, Riboldi P, and Cugno M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 117:1113-1117, 2006.
14. Asero R, Tedeschi A, Riboldi P, et al. Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy 63:176-180, 2008.
15. Lundblad RL, and White GC II. The interaction of thrombin with blood platelets. Platelets 16:373-385, 2005. (Pubitemid 41564334)
16. Martin JF, Trowbridge EA, Salmon G, and Plumb J. The biological significance of platelet volume: Its relationship to bleeding time, thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 32:443-460, 1983. (Pubitemid 14243216)
17. Haver VM, and Gear ARL. Functional fractionation of platelets. J Lab Clin Med 97:187-204, 1981. (Pubitemid 11136123)
18. Thompson CB, Eaton KA, Princiotta SM, et al. Size dependent platelet subpopulations: Relationship of platelet volume to ultrastructure, enzymatic activity and function. Br J Haematol 50:509-519, 1982. (Pubitemid 12184016)
19. Magen E, Mishal J, Zeldin Y, et al. Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. Am J Med Sci 339:504-508, 2010.
20. Staevska M, Popov T, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 125:676-682.c, 2010.
21. Zuberbier T, Balke M, Worm M, et al. Epidemiology of urticaria: A representative cross-sectional population survey. Clin Exp Dermatol 35:869-873, 2010.
22. Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: A prospective study of 139 patients. Allergy 59:869-873, 2004. (Pubitemid 39005829)
23. Nettis E, Dambra P, D'Oronzio L, et al. Reactivity to autologous serum skin test and clinical features in chronic idiopathic urticaria. Clin Exp Dermatol 27:29-31, 2002. (Pubitemid 34309934)
24. Kozel M, Mekkes J, Bossuyt P, and Bos J. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol 45:387-391, 2001. (Pubitemid 32800494)
25. Kulthanan K, Jiamton S, Thumpimukvatana N, and Pinkaew S. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 34:294-301, 2007. (Pubitemid 46535949)
26. Humphreys F, and Hunter J. The characteristics of urticaria in 390 patients. Br J Dermatol 138:635-638, 1998. (Pubitemid 28212248)
27. Staubach P, Onnen K, Vonend A, et al. Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: A placebo-controlled trial. Dermatology 212:150-159, 2006. (Pubitemid 43260731)
28. Gibbs BF. Human basophils as effectors and immunomodulators of allergic inflammation and innate immunity. Clin Exp Med 5:43-49, 2005. (Pubitemid 41153361)
29. Galli SJ, Tsai M, and Piliponsky AM. The development of allergic inflammation. Nature. 454:445-454, 2008.
30. Min B, Prout M, Hu-Li J, Zhu J, et al. Basophils produce IL-4 and accumulate in tissues after infection with a Th2-inducing parasite. J Exp Med 200:507-517, 2004. (Pubitemid 39121907)
31. Lourenço FD, Azor MH, Santos JC, et al. Activated status of basophils in chronic urticaria leads to interleukin-3 hyper-responsiveness and enhancement of histamine release induced by anti-IgE stimulus. Br J Dermatol 158:979-986, 2008. (Pubitemid 351521459)
32. Vasagar K, Vonakis BM, Gober LM, et al. Evidence of in vivo basophil activation in chronic idiopathic urticaria. Clin Exp Allergy 36:770-776, 2006. (Pubitemid 43972972)
33. Ferrer M, and Kaplan AP. Chronic urticaria: What is new, where are we headed. Allergol Immunopathol (Madr) 35:57-61, 2007. (Pubitemid 46846609)
34. Kasperska-Zajac A, Brzoza Z, and Rogala B. Plasma concentration of interleukin 6 (IL-6), and its relationship with circulating concentration of dehydroepiandrosterone sulfate (DHEA-S) in patients with chronic idiopathic urticaria. Cytokine 39:142-146, 2007. (Pubitemid 47520707)
35. Sainte-Laudy J, and Cado S. Comparison of the levels of histamine, tryptase, and interleukin-6 for the investigation of anaphylactoid drug reactions. Allerg Immunol (Paris) 30:209-211, 1998. (Pubitemid 28464620)
36. Lin RY, Trivino MR, Curry A, et al. Interleukin 6 and C-reactive protein levels in patients with acute allergic reactions: An emergency department based study. Ann Allergy Asthma Immunol 87:412-416, 2001. (Pubitemid 33063941)
37. Zamiri M, Jury CS, Dawe RS, et al. Reactivity to autologous serum skin test and relationship with complement levels in chronic idiopathic urticaria and angio-oedema. Clin Exp Dermatol 34:587-590, 2009.
38. Davies MD, Daoud MS, Kirby B, et al. Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis. J Am Acad Dermatol 38:899-905, 1998. (Pubitemid 28299180)
39. Ritchie RF, Palomaki GE, Neveux LM, et al. Reference distributions for complement proteins C3 and C4: A practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 18:1-8, 2004. (Pubitemid 38176995)
40. Moshage H. Cytokines and the hepatic acute phase response. J Pathol 181:257-266, 1997. (Pubitemid 27156836)
41. Morgan BP, and Gasque P. Extrahepatic complement biosynthesis: Where, when and why? Clin Exp Immunol 107:1-7, 1997. (Pubitemid 27019802)
42. El-Lati SG, Dahinden CA, and Church MK. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol 102:803-806, 1994. (Pubitemid 24144266)
43. Hartmann K, Henz BM, Krüger-Krasagakes S, et al. C3a and C5a stimulate chemotaxis of human mast cells. Blood 89:2863-2870, 1997. (Pubitemid 27172573)
44. Würnberg J, Nova E, Moreno LA, et al. AVENA Study Group. Inflammatory proteins are related to total and abdominal adiposity in a healthy adolescent population: The AVENA Study. Am J Clin Nutr 84:505-512, 2006. (Pubitemid 44713399)
45. van Greevenbroek MM, Jacobs M, van der Kallen CJ, et al. The cross-sectional association between insulin resistance and circulating complement C3 is partly explained by plasma alanine aminotransferase, independent of central obesity and general inflammation (the CODAM study). Eur J Clin Invest 41:372-379, 2011.
46. Kasperska-Zajac A, Sztylc J, Machura E, and Jop G. Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients. Clin Exp Allergy 41:1386-1391, 2011.